Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Cash from Financing Activities for 9 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 119.4% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $36.3 million (up 218.08% YoY), and the FY2025 full-year result was $33.0 million, up 169.22% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $6.1 million, down from $7.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $11.9 million in Q3 2025, with the low at -$178000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $3.3 million across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 212.66% — and 2025, when it jumped 6110.11%.
• Kiniksa Pharmaceuticals International's Cash from Financing Activities stood at $1.2 million in 2022, then sank by 41.6% to $695000.0 in 2023, then soared by 208.2% to $2.1 million in 2024, then soared by 257.52% to $7.7 million in 2025, then fell by 20.7% to $6.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $6.1 million (Q1 2026), $7.7 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.